Triveni Bio, a Waltham, MA-based biotech company providing a genetics-informed precision medicine approach for I&I disorders, raised $92M in Series A funding.
The round was led by Atlas Venture and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, and other investors.
The company intends to use the funds to support the advancement of TRIV-509 from preclinical development to a Phase 2a clinical trial and fuel a pipeline of novel antibodies with two additional development candidate nominations expected in 2024.
Led by CEO Vishal Patel, and Chief Scientific Officer Jennifer Dovey, Ph.D., Triveni Bio is a biotech company providing a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. Its lead antibody program (TRIV-509) targets kallikreins 5 and 7 (KLK5/7), promising targets for the treatment of atopic dermatitis, asthma, and other I&I indications.
Triveni Bio is the result of a merger between Amagma Therapeutics, which was founded by Tillman Gerngross, Ph.D. and Leonard Zon, M.D. with funding from Polaris; and Modify Therapeutics, which was founded and seeded by Atlas.
